TABLE 3.
Comparisons in clinical and procedural outcomes according to the occurrence of intracranial vasospasm requiring treatment with nimodipine after propensity score overlap weighting.
| Vasospasm treated with nimodipine | Effect size (95% CI) | p value | ||
|---|---|---|---|---|
| No | Yes | |||
| (n = 13,244) | (n = 249) | |||
| Clinical outcome | ||||
| Favorable outcome a | 5772 (43.5) | 82 (33.1) | 0.64 (0.45 to 0.92) | 0.017 |
| Excellent outcome b | 4018 (30.3) | 54 (21.6) | 0.63 (0.44 to 0.92) | 0.016 |
| 90‐day mortality | 3119 (23.6) | 67 (27.0) | 1.20 (0.89 to 1.64) | 0.23 |
| Intracranial hemorrhagic complications | ||||
| Any ICH | 5429 (41.0) | 117 (47.0) | 1.28 (0.96 to 1.71) | 0.095 |
| sICH | 1337 (10.1) | 27 (10.7) | 1.04 (0.51 to 2.13) | 0.90 |
| PH | 1701 (12.8) | 40 (16.2) | 1.30 (0.75 to 2.26) | 0.34 |
| 24 h ASPECTS shift, mean (95% CI) | −0.43 (−1.84 to 0.97) | −0.74 (−1.75 to 0.27) | −0.31 (−1.83 to 1.22) c | 0.69 |
| 24 h NIHSS shift, mean (95% CI) | −3.36 (−4.64 to −2.08) | −1.63 (−3.11 to −0.15) | 1.73 (0.95 to 2.52) c | <0.001 |
| Procedural outcomes | ||||
| Final mTICI score 2b, 2c or 3 | 11,130 (84.0) | 200 (80.4) | 0.78 (0.53 to 1.15) | 0.21 |
| Final mTICI score 2c–3 | 7627 (57.6) | 110 (44.0) | 0.58 (0.36 to 0.91) | 0.020 |
| Final mTICI score 3 | 5023 (38.0) | 59 (23.6) | 0.50 (0.28 to 0.90) | 0.021 |
| Procedural complication | 649 (4.9) | 29 (11.5) | 2.54 (1.54 to 4.20) | <0.001 |
| Perforations | 211 (1.6) | 7 (2.7) | 1.68 (0.52 to 5.44) | 0.39 |
| Emboli in a new territory | 437 (3.3) | 22 (8.9) | 2.82 (1.85 to 4.29) | <0.001 |
| Number of passes | 2 (1 to 3) | 3 (2 to 4) | 1.49 (1.24 to 1.79) | <0.0.001 |
Note: Values n (%) are estimated in the propensity score overlap weighted cohort unless otherwise indicated.
Abbreviations: ASPECTS, Alberta Stroke Program Early Computed Tomography Score; CI, confidence interval; ICH, intracerebral hemorrhage; IQR, interquartile range; mTICI, modified Thrombolysis In Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; PH, parenchymal hematoma of type 1 and 2; sICH, symptomatic intracerebral hemorrhage.
Prespecified primary outcome defined as a 90‐day modified Rankin Scale (mRS) score of 0–2, or equal to pre‐stroke mRS score.
Defined as a 90‐day mRS score of 0–1, or equal to pre‐stroke mRS score.
Baseline‐adjusted mean difference. Descriptive parameters and effect sizes (odds ratio or mean difference) were calculated after handling missing values for variables included in the propensity score using multiple imputations.